Multiomics Analysis of Tumor Microenvironment Reveals Gata2 and miRNA-124-3p as Potential Novel Biomarkers in Ovarian Cancer
- PMID: 28937943
- DOI: 10.1089/omi.2017.0115
Multiomics Analysis of Tumor Microenvironment Reveals Gata2 and miRNA-124-3p as Potential Novel Biomarkers in Ovarian Cancer
Abstract
Ovarian cancer is a common and, yet, one of the most deadly human cancers due to its insidious onset and the current lack of robust early diagnostic tests. Tumors are complex tissues comprised of not only malignant cells but also genetically stable stromal cells. Understanding the molecular mechanisms behind epithelial-stromal crosstalk in ovarian cancer is a great challenge in particular. In the present study, we performed comparative analyses of transcriptome data from laser microdissected epithelial, stromal, and ovarian tumor tissues, and identified common and tissue-specific reporter biomolecules-genes, receptors, membrane proteins, transcription factors (TFs), microRNAs (miRNAs), and metabolites-by integration of transcriptome data with genome-scale biomolecular networks. Tissue-specific response maps included common differentially expressed genes (DEGs) and reporter biomolecules were reconstructed and topological analyses were performed. We found that CDK2, EP300, and SRC as receptor-related functions or membrane proteins; Ets1, Ar, Gata2, and Foxp3 as TFs; and miR-16-5p and miR-124-3p as putative biomarkers and warrant further validation research. In addition, we report in this study that Gata2 and miR-124-3p are potential novel reporter biomolecules for ovarian cancer. The study of tissue-specific reporter biomolecules in epithelial cells, stroma, and tumor tissues as exemplified in the present study offers promise in biomarker discovery and diagnostics innovation for common complex human diseases such as ovarian cancer.
Keywords: multiomics; network medicine; ovarian cancer; transcriptome; tumor microenvironment.
Similar articles
-
Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.Oncol Rep. 2017 Jun;37(6):3543-3553. doi: 10.3892/or.2017.5612. Epub 2017 Apr 28. Oncol Rep. 2017. PMID: 28498428
-
Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective.PLoS One. 2018 Jul 18;13(7):e0200717. doi: 10.1371/journal.pone.0200717. eCollection 2018. PLoS One. 2018. PMID: 30020984 Free PMC article.
-
Identification of Prognostic Biomarker Signatures and Candidate Drugs in Colorectal Cancer: Insights from Systems Biology Analysis.Medicina (Kaunas). 2019 Jan 17;55(1):20. doi: 10.3390/medicina55010020. Medicina (Kaunas). 2019. PMID: 30658502 Free PMC article.
-
The clinical impact of intra- and extracellular miRNAs in ovarian cancer.Cancer Sci. 2020 Oct;111(10):3435-3444. doi: 10.1111/cas.14599. Epub 2020 Aug 27. Cancer Sci. 2020. PMID: 32750177 Free PMC article. Review.
-
microRNAs as biomarkers of ovarian cancer.Expert Rev Anticancer Ther. 2020 May;20(5):373-385. doi: 10.1080/14737140.2020.1760095. Epub 2020 May 3. Expert Rev Anticancer Ther. 2020. PMID: 32326768 Review.
Cited by
-
USP43 impairs cisplatin sensitivity in epithelial ovarian cancer through HDAC2-dependent regulation of Wnt/β-catenin signaling pathway.Apoptosis. 2024 Feb;29(1-2):210-228. doi: 10.1007/s10495-023-01873-x. Epub 2023 Dec 12. Apoptosis. 2024. PMID: 38087046 Free PMC article.
-
Disclosing Potential Key Genes, Therapeutic Targets and Agents for Non-Small Cell Lung Cancer: Evidence from Integrative Bioinformatics Analysis.Vaccines (Basel). 2022 May 12;10(5):771. doi: 10.3390/vaccines10050771. Vaccines (Basel). 2022. PMID: 35632527 Free PMC article.
-
Artificial intelligence in cancer target identification and drug discovery.Signal Transduct Target Ther. 2022 May 10;7(1):156. doi: 10.1038/s41392-022-00994-0. Signal Transduct Target Ther. 2022. PMID: 35538061 Free PMC article. Review.
-
Characterization of the Potential Role of NTPCR in Epithelial Ovarian Cancer by Integrating Transcriptomic and Metabolomic Analysis.Front Genet. 2021 Sep 1;12:695245. doi: 10.3389/fgene.2021.695245. eCollection 2021. Front Genet. 2021. PMID: 34539736 Free PMC article.
-
miRNA-Based Signature Associated With Tumor Mutational Burden in Colon Adenocarcinoma.Front Oncol. 2021 Jun 23;11:634841. doi: 10.3389/fonc.2021.634841. eCollection 2021. Front Oncol. 2021. PMID: 34262855 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
